Browse our 650+ Publications​

Latest Publications

Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma

Huuhtanen J, et al.
April 2023
Authors and Affiliates
Jani Huuhtanen 1,2,3,4, Henna Kasanen 1,2,4, Katriina Peltola 4,5, Tapio Lönnberg 6, Virpi Glumoff 7, Oscar Brück 1,2,4, Olli Dufva 1,2,4, Karita Peltonen 1,2,4, Johanna Vikkula 3, Emmi Jokinen 1,2,3,4, Mette Ilander 1,2, Moon Hee Lee 1,2,4, Siru Mäkelä 5, Marta Nyakas 8, Bin Li 9, Micaela Hernberg 5, Petri Bono 5, Harri Lähdesmäki 3, Anna Kreutzman 1,2, Satu Mustjoki 1,2,4; 1 Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. 2 Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 3 Department of Computer Science, Aalto University, Espoo, Finland. 4 iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. 5 Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 6 Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. 7 Research Unit of Biomedicine, Medical Microbiology and Immunology, University of Oulu, Oulu, Finland. 8 Oslo University Hospital-Radiumhospitalet, Oslo, Norway. 9 Bristol Myers Squibb (BMS) Research and Development, Princeton, New Jersey, USA.

Clonal composition and persistence of antigen-specific circulating T follicular helper cells

Hu M, e al.
April 2023
Authors and Affiliates
Mengyun Hu 1,2 , Samuele Notarbartolo 1,3 , Mathilde Foglierini 1,4 , Sandra Jovic 1 , Federico Mele 1 , David Jarrossay 1 , Antonio Lanzavecchia 5 , Antonino Cassotta 1 , Federica Sallusto 1,6; 1 Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. 2 Present address: Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA. 3 Present address: National Institute of Molecular Genetics, Milano, Italy. 4 Present address: Service d'immunologie et d'allergie, CHUV, Lausanne, Switzerland. 5 National Institute of Molecular Genetics, Milano, Italy. 6 Institute of Microbiology, ETH Zurich, Zurich, Switzerland.

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

Friedrich MJ, et al.
April 2023
Authors and Affiliates
Mirco J Friedrich 1 , Paola Neri 2 , Niklas Kehl 3 , Julius Michel 3 , Simon Steiger 4 , Michael Kilian 3 , Noémie Leblay 5 , Ranjan Maity 5 , Roman Sankowski 6 , Holly Lee 2 , Elie Barakat 5 , Sungwoo Ahn 5 , Niels Weinhold 7 , Karsten Rippe 8 , Lukas Bunse 3 , Michael Platten 9 , Hartmut Goldschmidt 10 , Carsten Müller-Tidow 10 , Marc-Steffen Raab 11 , Nizar J Bahlis 12; 1 Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: mfriedri@broadinstitute.org. 2 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada. 3 Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 4 Division of Chromatin Networks, BioQuant Center & German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. 5 Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada. 6 Department of Neuropathology, Freiburg University Hospital, Freiburg, Germany. 7 Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany. 8 Division of Chromatin Networks, BioQuant Center & German Cancer Research Center (DKFZ), Heidelberg, Germany. 9 Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Helmholtz Institute of Translational Oncology (HI-TRON), Mainz, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim Germany. 10 Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany. 11 Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: marc.raab@med.uni-heidelberg.de. 12 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada. Electronic address: nbahlis@ucalgary.ca.

Cross-reactivity influences changes in human influenza A virus and Epstein Barr virus specific CD8 memory T cell receptor alpha and beta repertoires between young and old

Clark F, et al.
April 2023
Authors and Affiliates
Fransenio Clark 1 , Anna Gil 1 , Ishwor Thapa 2 , Nuray Aslan 1 , Dario Ghersi 2 , Liisa K Selin 1; 1 Department of Pathology, University of Massachusetts Medical School, Worcester, MA, United States. 2 School of Interdisciplinary Informatics, University of Nebraska at Omaha, Omaha, NE, United States.

Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes

Chu Y, et al.
April 2023
Authors and Affiliates
Yaya Chu 1 , Jordan Milner 1 , Margaret Lamb 2,3 , Elena Maryamchik 4,5 , Olivia Rigot 1 , Janet Ayello 1 , Lauren Harrison 1 , Rosemarie Shaw 1 , Gregory K Behbehani 6 , Elaine R Mardis 3,7 , Katherine Miller 7 , Lakshmi Prakruthi Rao Venkata 7 , Hsiaochi Chang 6 , Dean Lee 2,3 , Elana Rosenthal 1 , Stephan Kadauke 4 , Nancy Bunin 5,8 , Julie-An Talano 9 , Bryon Johnson 10 , Yongping Wang 4,5 , Mitchell S Cairo 1,11,12,13; 1 Department of Pediatrics, New York Medical College, Valhalla, New York, USA. 2 Department of Hematology/Oncology/Bone Marrow Transplant, Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio, USA. 3 Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA. 4 Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 5 Perlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 6 Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, Ohio, USA. 7 The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. 8 Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 9 Department of Pediatrics, Hematology/Oncology and BMT, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 10 Department of Medicine, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 11 Department of Medicine, New York Medical College, Valhalla, New York, USA. 12 Department of Microbiology, Immunology, and Pathology, New York Medical College, Valhalla, New York, USA. 13 Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York, USA.

The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer

Chow A, et al.
April 2023
Authors and Affiliates
Andrew Chow 1 , Fathema Z Uddin 2 , Michael Liu 2 , Anton Dobrin 3 , Barzin Y Nabet 4 , Levi Mangarin 5 , Yonit Lavin 2 , Hira Rizvi 6 , Sam E Tischfield 7 , Alvaro Quintanal-Villalonga 2 , Joseph M Chan 2 , Nisargbhai Shah 2 , Viola Allaj 2 , Parvathy Manoj 2 , Marissa Mattar 8 , Maximiliano Meneses 8 , Rebecca Landau 8 , Mariana Ward 8 , Amanda Kulick 8 , Charlene Kwong 8 , Matthew Wierzbicki 8 , Jessica Yavner 8 , Jacklynn Egger 6 , Shweta S Chavan 7 , Abigail Farillas 2 , Aliya Holland 5 , Harsha Sridhar 2 , Metamia Ciampricotti 2 , Daniel Hirschhorn 5 , Xiangnan Guan 4 , Allison L Richards 7 , Glenn Heller 9 , Jorge Mansilla-Soto 10 , Michel Sadelain 11 , Christopher A Klebanoff 12 , Matthew D Hellmann 13 , Triparna Sen 2 , Elisa de Stanchina 8 , Jedd D Wolchok 14 , Taha Merghoub 15 , Charles M Rudin 16; 1 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: chowa1@mskcc.org. 2 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4 Department of Oncology Biomarker Development, Genentech, South San Francisco, CA, USA. 5 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6 Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7 Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9 Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 11 Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 13 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 14 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 15 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: tmerghoub@med.cornell.edu. 16 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rudinc@mskcc.org.

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.

Phillips TJ, et al.
Blood Advances
April 2023
Authors and Affiliates
Tycel J. Phillips, MD1 David Bond, MD2 Radihka Takiar, MD3 Karson Kump, PhD3 Malalthi Kandarpa, PhD3 Philip Boonstra, PhD3 Tera Lynn Mayer, NP3 Victoria Nachar, Pharm D3 Ryan A. Wilcox, MD, PhD3 Shannon A. Carty, MD3 Yasmin H. Karimi, MD3 Zaneta Nikolovska-Coleska, PhD3 Mark S. Kaminski, MD3 Alex F. Herrera, MD1 Kami Maddocks, MD2 Leslie Popplewell, MD1 Alexey V. Danilov, MD1 1. City of Hope National Medical Center, Duarte, CA, 91010, 2. The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, 3. The University of Michigan Rogel Cancer Center, Ann Arbor, MI 48105

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.

Cassaday RD, et al.
March 2023
Authors and Affiliates
Ryan D. Cassadaya,b, Lucas C. Zarlinga, Kelsey-Leigh A. Garciaa, Olga Sala-Torrab, Philip A. Stevensonc, Christen H. Martinoa,b, Yajuan J. Liud, Min Fangb,d, Mary-Elizabeth M. Percivala,b, Anna B. Halperna,b, Pamela S.Beckera,b,e, Vivian G. Oehlera,b, Andrei R. Shustova, Jason P. Coopera,b, Johnnie J. Orozcoa,b,Paul C. Hendriea,b, Roland B. Waltera,b , Jerald P. Radicha,b, Lorinda A. Somaf and Elihu H. Esteya,b aDepartment of Medicine, University of Washington, Seattle, WA, USA; bClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; cClinical Statistics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; dDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; eDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA; fDepartment of Pathology, City of Hope National Medical Center, Duarte,CA, USA

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.

Fonseca R, et al.
Blood Cancer Journal
March 2023
Authors and Affiliates
Rodrigo Fonseca 1, Mariano Arribas 1, Julia E. Wiedmeier-Nutor1, Yael N. Kusne1, Miguel González Vélez2, Heidi E. Kosiorek3, Richard (Duke) J. Butterfield3, Ilan R. Kirsch4, Joseph R. Mikhael 5, A. Keith Stewart6, Craig Reeder 1, Jeremy Larsen1, P. Leif Bergsagel 1 and Rafael Fonseca 1 1Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA. 2Dignity Health Cancer Institute, Phoenix, AZ, USA. 3Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA. 4Translational Medicine, Adaptive Biotechnologies, Seattle, WA, USA. 5Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 6Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Combination IFNβ and membrane-stable CD40L maximize tumor dendritic cell activation and lymph node trafficking to elicit systemic T-cell immunity

Zheng H, et al.
February 2023
Authors and Affiliates
Hong Zheng 1, Xiaoqing Yu 2, Mohammed L Ibrahim 3, Dana Foresman 3, Mengyu Xie 4, Joseph O Johnson 2, Theresa A Boyle 2, Brian Ruffell 2, Bradford A Perez 5, Scott J Antonia 6, Neal Ready 7, Andreas N Saltos 8, Mark J Cantwell 9, Amer A Beg 10; 1 Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 2 Moffitt Cancer Center, Tampa, FL, United States. 3 Moffitt Cancer Center, Tampa, United States. 4 Moffitt Cancer Center, United States. 5 H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 6 Duke University School of Medicine, Durham, NC, United States. 7 Duke Medical Center, Durham, NC, United States. 8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States. 9 Memgen, Inc., Houston, TX, United States. 10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.